Xeloda, Capecitabine Newswire (Page 5)

Xeloda, Capecitabine Newswire (Page 5)

Comprehensive Real-Time News Feed for Xeloda, Capecitabine (generic). (Page 5)

Results 81 - 100 of 131 in Xeloda, Capecitabine (generic)

  1. Case Western Reserve Named to New National Colorectal Cancer Dream TeamRead the original story

    Apr 3, 2017 | Newswise

    Case Western Reserve University School of Medicine and the Case Comprehensive Cancer Center have been named to a new colorectal cancer dream team that was announced today at the annual meeting of the American Association for Cancer Research in Washington, D.C. The dream team comprises scientists, clinicians, technicians, and other experts from Memorial Sloan Kettering Cancer Center, Yale University, Cornell University, and CWRU/Case Comprehensive Cancer Center.

    Comment?

  2. ACETO Subsidiary, Rising Pharmaceuticals, Launches Capecitabine Tablets, 150 & 500 mgRead the original story

    Mar 28, 2017 | World News Report

    ACETO Corporation , an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals, its finished dosage form generics subsidiary, has launched Capecitabine Tablets, 150 & 500 mg, an AB-rated generic version of Xeloda® Tablets from Hoffman La Roche.  Capecitabine Tablets, 150 & 500 mg, which are indicated for the treatment of metastatic breast cancer, had U.S. sales of approximately $393 million for the 12 months ending December 2016, according to IMS Health.

    Comment?

  3. BRIEF-Aceto's unit launches Capecitabine Tablets, 150 & 500 MGRead the original story w/Photo

    Mar 28, 2017 | Reuters

    * Bank of Canada Governor says in era where will probably be some changes to trade architecture, welcomes "dusting off" of NAFTA

    Comment?

  4. Malignant acrospiroma: a case report in the era of next generation sequencingRead the original story w/Photo

    Mar 26, 2017 | BioMed Central

    Malignant acrospiroma is a rare tumor of the eccrine sweat glands accounting for around 6% of all malignant eccrine tumors. Typically, it presents as large ulcerated nodules, and diagnosis can be challenging as it has great overlap with its benign counterpart.

    Comment?

  5. Immunomedics Announces Publication of Results in Journal of Clinical...Read the original story w/Photo

    Mar 15, 2017 | Drugs.com

    Immunomedics, Inc., today announced that sacituzumab govitecan , the Company's lead antibody-drug conjugate , was highly active in heavily-pretreated patients with metastatic triple-negative breast cancer who received a median of five lines of therapy since diagnosis. Results from this single-arm Phase 2 study were published online in the Journal of Clinical Oncology,1 the official journal of the American Society of Clinical Oncology , which is a premier peer-reviewed, publication in clinical cancer research.

    Comment?

  6. Divi's Labs' Vizag plant banned from shipping to USRead the original story w/Photo

    Mar 23, 2017 | Drug Researcher

    Indian API firm Divi's Laboratories has been banned from shipping drug ingredients made at its Vizag plant to the US. The firm announced the import alert in a Bombay Stock Exchange on March 21 , explaining that the ban applies to its Unit-II at Visakhapatnam - also known as Vizag - in Andhra Pradesh, India.

    Comment?

  7. Cascadian Therapeutics: Worth Much More Than The Present Share PriceRead the original story w/Photo

    Mar 23, 2017 | Seeking Alpha

    Despite misgivings about management, the company possesses a promising clinical candidate in tucatinib that is worth much more than the present valuation. Potentially positive developments in the next year could cause a revaluation of shares, offering long term investors a chance to take profits and risk of the table.

    Comment?

  8. USFDA issues import alert on Divi's Lab Vizag unit6 min agoRead the original story w/Photo

    Mar 20, 2017 | India.com

    New Delhi, Mar 21 Drug firm Divi's Laboratories today said the US health regulator has issued an import alert on the products manufactured at one of its units in Visakhapatnam, Andhra Pradesh. "USFDA has issued an import alert 66-40 on March 20, 2017 on the products manufactured at the company's Unit-II at Visakhapatnam, Andhra Pradesh," Divi's Laboratories said in a BSE filing.

    Comment?

  9. Patheon ramping up former Roche site to fulfil demand for Western APIsRead the original story w/Photo

    Mar 20, 2017 | In-PharmaTechnologist.com

    Patheon believes it can triple revenues at its recently acquired Roche facility in South Carolina due to a shortage of Western active pharmaceutical ingredient capacity. The contract development and manufacturing organisation acquired the Florence, South Carolina plant in November 2016 , and signed a multi-year deal to supply Roche with a variety of APIs - including the active ingredient for the chemotherapy drug Xeloda - from the site.

    Comment?

  10. Positive Clinical Results for Using Myriad's BRACAnalysis...Read the original story w/Photo

    Mar 20, 2017 | JD Supra

    Myriad Genetics recently announced clinical results showing that its BRACAnalysis CDx test was able to identify patients with HER2-negative metastatic breast cancer who had improved response with Lynparza , AstraZeneca's PARP inhibitor. The results are based on a collaborative effort between Myriad Genetics and AstraZeneca for identification and treatment of patients with metastatic breast cancer and underlying BRCA 1/2 mutations.

    Comment?

  11. Immunomedics Announces Publication Of Results In Demonstrating...Read the original story

    Mar 14, 2017 | BioSpace

    Immunomedics Announces Publication Of Results In Journal Of Clinical Oncology , Demonstrating Treatment With Sacituzumab Govitecan Produces Early And Durable Responses In Patients With Metastatic Triple-Negative Breast Cancer /PRNewswire/ -- Immunomedics, Inc. , today announced that sacituzumab govitecan , the Company's lead antibody-drug conjugate , was highly active in heavily-pretreated patients with metastatic triple-negative breast cancer who received a median of five lines of therapy since diagnosis.

    Comment?

  12. Cascadian Therapeutics Announces Changes To Board Of DirectorsRead the original story

    Mar 13, 2017 | BioSpace

    Cascadian Therapeutics, Inc. , a clinical-stage biopharmaceutical company, today announced that Robert W. Azelby has been appointed to the Company's Board of Directors. Mr. Azelby is a biotechnology and pharmaceutical industry veteran.

    Comment?

  13. Cascadian Therapeutics Reports Fourth Quarter and Full Year 2016 Financial ResultsRead the original story

    Mar 9, 2017 | Customer Interaction Solutions

    Cascadian Therapeutics, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2016. "In 2016, we focused our efforts on the development of tucatinib for late-stage HER2-positive metastatic breast cancer for patients with and without brain metastases and amended our ongoing HER2CLIMB study by increasing the sample size so that, if successful, the trial could serve as a single pivotal trial to support registration," said Scott Myers, President and CEO of Cascadian Therapeutics.

    Comment?

  14. Patients with pathological stage N2 rectal cancer treated with early...Read the original story w/Photo

    Mar 8, 2017 | BioMed Central

    In this era of oxaliplatin-based adjuvant therapy, the optimal sequence in which chemoradiotherapy should be administered for pathological stage N2 rectal cancer is unknown. The aim of this study was to investigate this sequence.

    Comment?

  15. Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and...Read the original story

    Mar 6, 2017 | CiteULike

    Capecitabine is not considered a standard agent in the adjuvant treatment of early breast cancer. The results of this study suggest that addition of adjuvant capecitabine to a regimen that contains docetaxel, epirubicin, and cyclophosphamide improves survival outcomes of patients with triple-negative breast cancer .

    Comment?

  16. Puma Biotechnology Reports Fourth Quarter and Full Year 2016 Financial ResultsRead the original story w/Photo

    Mar 1, 2017 | Business Wire

    Unless otherwise stated, all comparisons are for the fourth quarter and full year 2016 compared to the fourth quarter and full year 2015. Based on accounting principles generally accepted in the United States , Puma reported a net loss applicable to common stock of $72.7 million, or $2.04 per share, for the fourth quarter of 2016, compared to a net loss of $61.7 million, or $1.90 per share, for the fourth quarter of 2015.

    Comment?

  17. The role of neoadjuvant therapy in pancreatic cancer: a review.Read the original story

    Feb 17, 2017 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. Controversy remains regarding neoadjuvant approaches in the treatment of pancreatic cancer.

    Comment?

  18. LYNPARZAa (olaparib) Meets Primary Endpoint in Phase III Trial in...Read the original story

    Feb 17, 2017 | Customer Interaction Solutions

    AstraZeneca today announced positive results from its Phase III OlympiAD trial comparing LYNPARZA tablets to physician's choice of a standard of care chemotherapy in the treatment of patients with HER2-negative metastatic breast cancer harboring germline BRCA1 or BRCA2 mutations.1 Patients treated with LYNPARZA showed a statistically-significant and clinically-meaningful improvement in progression-free survival compared with those who received chemotherapy .

    Comment?

  19. Lynparza meets primary endpoint in Phase III trial in BRCA-mutated metastatic breast cancerRead the original story

    Feb 17, 2017 | PressReleasePoint

    AstraZeneca today announced positive results from its Phase III OLYMPIAD trial comparing Lynparza tablets to physician's choice of a standard of care chemotherapy in the treatment of patients with HER2-negative metastatic breast cancer harbouring germline BRCA1 or BRCA2 mutations. Patients treated with Lynparza showed a statistically-significant and clinically-meaningful improvement in progression-free survival compared with those who received chemotherapy .

    Comment?

  20. AstraZeneca reports positive results from breast cancer drug trialRead the original story w/Photo

    Feb 17, 2017 | Live Charts

    AstraZeneca on Friday reported positive results from its Phase III OLYMPIAD trial of its breast cancer treatment Lynparza . Patients treated with Lynparza showed a statistically-significant and clinically-meaningful improvement in progression-free survival compared with those who received chemotherapy , the company said.

    Comment?